|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.26 0.00 (0.00%) as of 4:30 Mon 1/29
|
|
Download |
|
|
| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
6,330,000 |
| Market
Cap: |
1.65(M) |
| Last
Volume: |
1,098,390 |
Avg
Vol: |
1,095,381 |
| 52
Week Range: |
$0.2601 - $0.67 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GeoVax Labs is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using vector vaccine platforms. Co.'s product pipeline includes: Coronavirus Vaccine Programs, which includes COVID-19, GEO-CM04S1 for Immunocompromised Patients, GEO-CM04S1 as a Booster Vaccine and GEO-CM02 as a Pan-Coronavirus Vaccine; and Cancer Immunotherapy Programs, which are focused on Gedeptin® and MUC1-based Immunotherapy. Additional research and development programs include: Hemorrhagic Fever Virus Vaccines, which includes Ebola, Sudan, Marburg and Lassa; Other Infectious Disease Programs, which includes GEO-ZM02 for Zika, and GEO-MM02 for Malaria.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
17,673 |
72,413 |
137,877 |
| Total Buy Value |
$0 |
$27,821 |
$58,020 |
$112,425 |
| Total People Bought |
0 |
3 |
3 |
5 |
| Total Buy Transactions |
0 |
4 |
7 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dodd David A |
President, CEO |
• • – |
2024-02-22 |
4 |
B |
$2.27 |
$18,663 |
D/D |
8,209 |
18,661 |
2.81 |
- |
|
| Dodd David A |
President, CEO |
• • – |
2024-02-21 |
4 |
B |
$2.15 |
$1,118 |
D/D |
520 |
10,452 |
2.73 |
- |
|
| Reynolds Mark |
CFO |
• • – |
2024-02-07 |
4 |
B |
$2.77 |
$5,540 |
D/D |
2,000 |
7,213 |
2.74 |
- |
|
| Mckee Kelly T. Jr. |
Chief Medical Officer |
• • – |
2023-12-22 |
4 |
B |
$0.36 |
$2,500 |
D/D |
6,944 |
35,782 |
2.66 |
-29% |
|
| Mckee Kelly T. Jr. |
Chief Medical Officer |
• • – |
2023-09-25 |
4 |
B |
$0.52 |
$5,020 |
D/D |
9,653 |
28,838 |
2.74 |
-49% |
|
| Dodd David A |
President, CEO |
• • – |
2023-08-25 |
4 |
B |
$0.57 |
$20,000 |
D/D |
35,087 |
148,957 |
2.81 |
-35% |
|
| Reynolds Mark |
CFO |
• • – |
2023-08-18 |
4 |
B |
$0.52 |
$5,179 |
D/D |
10,000 |
78,184 |
2.74 |
-28% |
|
| Dodd David A |
President, CEO |
• • – |
2023-04-24 |
4 |
B |
$0.64 |
$20,445 |
D/D |
32,000 |
113,870 |
2.81 |
-9% |
|
| Reynolds Mark |
CFO |
• • – |
2023-04-20 |
4 |
B |
$0.63 |
$5,040 |
D/D |
8,000 |
68,184 |
2.74 |
-10% |
|
| Chase Randal D |
Director |
• • – |
2022-09-21 |
4 |
B |
$1.10 |
$11,000 |
D/D |
10,000 |
36,613 |
2.39 |
-16% |
|
| Sharkey John W. |
VP, Business Development |
• • – |
2022-07-01 |
4 |
B |
$0.82 |
$820 |
D/D |
1,000 |
2,860 |
2.66 |
-5% |
|
| Mckee Kelly T. Jr. |
Chief Medical Officer |
• • – |
2022-06-27 |
4 |
B |
$1.12 |
$5,000 |
D/D |
4,464 |
19,185 |
2.74 |
-16% |
|
| Chase Randal D |
Director |
• • – |
2022-06-21 |
4 |
B |
$1.21 |
$12,100 |
D/D |
10,000 |
26,613 |
2.39 |
-25% |
|
| Sharkey John W. |
VP, Business DevelopmentOffice |
• – – |
2022-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,860 |
|
-26% |
|
| Reynolds Mark |
CFO |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$300,920 |
D/D |
60,184 |
60,184 |
2.74 |
104% |
|
| Mcnally Robert T |
Director |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$269,625 |
D/D |
53,925 |
53,925 |
2.39 |
104% |
|
| Chase Randal D |
Director |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$83,065 |
D/D |
16,613 |
16,613 |
2.39 |
104% |
|
| Dodd David A |
President, CEO |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$409,350 |
D/D |
81,870 |
81,870 |
2.81 |
104% |
|
| Spencer John N Jr |
Director |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$105,120 |
D/D |
21,024 |
21,024 |
2.39 |
104% |
|
| Kollintzas Dean G |
Director |
• • – |
2020-09-29 |
4 |
B |
$5.00 |
$59,935 |
D/D |
11,987 |
11,987 |
2.39 |
104% |
|
| Chase Randal D |
Director |
• • – |
2015-05-05 |
4 |
B |
$0.19 |
$1,900 |
D/D |
10,000 |
40,000 |
2.31 |
- |
|
| Reynolds Mark |
CFO |
• • – |
2015-04-23 |
4 |
B |
$0.18 |
$1,780 |
D/D |
10,000 |
66,000 |
2.66 |
- |
|
| Reynolds Mark |
CFO |
• • – |
2015-04-22 |
4 |
B |
$0.17 |
$3,435 |
D/D |
20,000 |
56,000 |
2.66 |
- |
|
| Chase Randal D |
Director |
• • – |
2015-04-20 |
4 |
B |
$0.17 |
$5,100 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
| Spencer John N Jr |
Director |
• • – |
2015-04-20 |
4 |
B |
$0.17 |
$3,015 |
D/D |
18,000 |
46,625 |
2.31 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
